Australia, Jan. 15 -- Avidity Biosciences Inc., owns the trademark (2596683) for 'CDUX' till Oct. 21, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations; therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopul...